The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Using MRD to better understand treatment responses in patients with CLL
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, summarizes the importance of using measurable residual disease (MRD) to better understand and classify patient responses to therapy in chronic lymphocytic leukemia (CLL), and further highlights how MRD can be used to improve patient outcomes. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
